DDInter125 DDInter1082
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Asenapine {u} (Compound) binds {v} (Gene) HRH2
Asenapine {u} (Compound) downregulates {v} (Gene) IGFBP2
Asenapine {u} (Compound) causes {v} (Side Effect) Parkinsonism
Asenapine (Compound) resembles Loxapine (Compound)
Asenapine (Compound) binds HRH2 (Gene)
Asenapine (Compound) downregulates IGFBP2 (Gene)
Asenapine (Compound) causes Parkinsonism (Side Effect)